Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ ... personalized medicine, and artificial intelligence, while the aging population and growing healthcare ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

What started as off-label use by celebrities and social media influencers for cutting weight became a viral sensation as type 2 diabetes medicine ... from Viking Therapeutics Inc. (NASDAQ: VKTX ...

It has been roughly 3 months since my last Viking Therapeutics, Inc. (NASDAQ:VKTX) article, where I discussed how VKTX had dropped 50% despite strong clinical progress in obesity and NASH due to ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which ...

Pfizer Inc. PFE announced on Monday that it will ... which resolved after discontinuation of danuglipron. Also Read: Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners ...

Viking Therapeutics, Inc. (VKTX) closed the latest trading day at $23.91, indicating a -0.99% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0 ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...